Replies to post #138365 on Innovation Pharmaceuticals Inc (IPIX)

[biodoc]

To Infinity..

I think it's fair to say that we're not seeing acute toxicities in Phase 1 when kevetrin is given weekly which is really encouraging with the apparent signs of efficacy. I agree, we do not know how well kevetrin will be tolerated with more frequent dosing and I don't think we have a good read on the types of side effects that are most likely to occur. As you are well aware, the dosing strategy could greatly impact the side effects that we will eventually see.

I'm optimistic that with the Phase 1 study demonstrating safety at relatively high but widely spaced doses, we have a very good starting point for Phase 2. No doubt, Cellceutix is now armed with much more PK/PD info to plan a therapeutic strategy for kevetrin which is really the goal of Phase 2.